Emerging strategies for hepatocellular carcinoma surveillance: Abbreviated MRI, biomarkers and benefit stratification.

Abbreviated MRI protocols and blood-based biomarkers show promise for improving hepatocellular carcinoma surveillance accuracy and patient adherence.

• Why it matters: Current ultrasound and AFP screening have limited sensitivity for early-stage HCC and poor adherence, creating a critical need for more effective, patient-friendly methods that can improve clinical outcomes.
• What they did: The study reviews emerging HCC surveillance strategies, including dynamic contrast-enhanced and non-contrast abbreviated MRI, as well as blood-based biomarker panels, emphasizing the importance of benefit-based patient selection.
• The result: Implementing validated, benefit-stratified surveillance approaches could enhance early detection and treatment, ultimately leading to better clinical outcomes, even among patients at varying levels of HCC risk.